{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:50:01Z","timestamp":1789678201146,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cllc.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:10:21Z","timestamp":1719677421000},"page":"e362-e368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Martin","family":"Reck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuli","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Edmondson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Zoffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ashraf","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebibe","family":"Varol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Penrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.06.005_bib0001","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.2.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. Accessed March 6, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"4","key":"10.1016\/j.cllc.2024.06.005_bib0002","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.06.005_bib0003","unstructured":"Genentech, Inc. TECENTRIQ (atezolizumab) highlights of prescribing information. 2022. Available at https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed March 8, 2023."},{"key":"10.1016\/j.cllc.2024.06.005_bib0004","unstructured":"Merck. KEYTRUDA (pembrolizumab) highlights of prescribing information. 2023. Available at https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed March 8, 2023."},{"key":"10.1016\/j.cllc.2024.06.005_bib0005","unstructured":"Bristol Myers Squibb. OPDIVO (nivolumab) highlights of prescribing information. 2023. Available at https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed March 8, 2023."},{"issue":"3","key":"10.1016\/j.cllc.2024.06.005_bib0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jval.2019.10.015","article-title":"Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting","volume":"23","author":"Sullivan","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.cllc.2024.06.005_bib0007","unstructured":"Latimer NR, Abrams KR. NICE decision support unit technical support documents NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. London: National Institute for Health and Care Excellence (NICE). 2014."},{"issue":"1","key":"10.1016\/j.cllc.2024.06.005_bib0008","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.2158","article-title":"Estimands for overall survival in clinical trials with treatment switching in oncology","volume":"21","author":"Manitz","year":"2022","journal-title":"Pharm Stat"},{"issue":"21","key":"10.1016\/j.cllc.2024.06.005_bib0009","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.005_bib0011","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cam4.643","article-title":"Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy","volume":"5","author":"Latimer","year":"2016","journal-title":"Cancer Med"},{"issue":"22","key":"10.1016\/j.cllc.2024.06.005_bib0012","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.005_bib0013","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.005_bib0014","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/0962280214557578","article-title":"Adjusting for treatment switching in randomised controlled trials\u2014a simulation study and a simplified two-stage method","volume":"26","author":"Latimer","year":"2014","journal-title":"Stat Methods Med Res"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.005_bib0015","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models","volume":"20","author":"Robins","year":"1991","journal-title":"Commun Stat Theory Methods"},{"issue":"17","key":"10.1016\/j.cllc.2024.06.005_bib0016","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/sim.1219","article-title":"Estimating a treatment effect in survival studies in which patients switch treatment","volume":"21","author":"Branson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cllc.2024.06.005_bib0017","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.1016\/j.annonc.2022.07.1152","article-title":"1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer","volume":"33","author":"Reck","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.005_bib0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.005_bib0019","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.06.005_bib0021","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annonc.2022.02.012","article-title":"3MO first-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: updated overall survival results from the phase III CameL-sq trial","volume":"33","author":"Zhou","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.06.005_bib0022","doi-asserted-by":"crossref","first-page":"ii77","DOI":"10.1093\/annonc\/mdz094.003","article-title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study","volume":"30","author":"Reinmuth","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.06.005_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lungcan.2021.01.026","article-title":"Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: post hoc analyses from the phase 3 JAVELIN Lung 200 trial","volume":"154","author":"Park","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.06.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2021.100640","article-title":"Assessing the influence of subsequent immunotherapy on overall survival in patients with unresectable stage III non-small cell lung cancer from the PACIFIC study","volume":"95","author":"Ouwens","year":"2021","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.005_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0962280216642264","article-title":"Assessing methods for dealing with treatment switching in clinical trials: a follow-up simulation study","volume":"27","author":"Latimer","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.005_bib0026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2288-11-4","article-title":"Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study","volume":"11","author":"Morden","year":"2011","journal-title":"BMC Med Res Method"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.005_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12874-024-02140-6","article-title":"A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study","volume":"24","author":"Latimer","year":"2024","journal-title":"BMC Med Res Method"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.005_bib0028","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials\u2014economic evaluation context: methods, limitations, and recommendations","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Making"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:48:39Z","timestamp":1729871319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525730424001311"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}